Lisata Therapeutics, Inc. Common Stock (LSTA) is a publicly traded Healthcare sector company. As of May 21, 2026, LSTA trades at $3.18 with a market cap of $28.41M and a P/E ratio of -1.65. LSTA moved +1.60% today. Year to date, LSTA is +64.77%; over the trailing twelve months it is +24.71%. Its 52-week range spans $1.81 to $5.07. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces LSTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Law Firm Probes Lisata Therapeutics’ $4 Share Sale Plus Two CVRs: Lisata Therapeutics agreed to be acquired by Kuva Labs for $4.00 per share in cash plus two non-tradeable contingent value rights under specific performance conditions. Halper Sadeh LLC is investigating potential breaches of fiduciary duty in the deal and invites shareholders to pursue additional relief on a contingent fee basis.
| Metric | Value |
|---|---|
| Price | $3.18 |
| Market Cap | $28.41M |
| P/E Ratio | -1.65 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.07 |
| 52-Week Low | $1.81 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $170.00K |
| Net Income | $-16.59M |
| Gross Margin | 0.00% |
1 analysts cover LSTA: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.